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Abstract  (150 words) 
Introduction - Isolated Mediastinal Lymphadenopathy (IML) is an increasingly 
common finding as a result of the ubiquity of cross-sectional thoracic imaging.  
 
Objectives - We investigated the performance of Endobronchial-Ultrasound Guided 
Transbronchial Needle-Aspiration (EBUS-TBNA) in establishing a pathological 
diagnosis in patients with IML. 
 
Methods – Retrospective examination of all consecutive EBUS-TBNA examinations 
performed over 4 years at a tertiary referral centre. Final diagnosis was made using 
pathology reports, correlated with clinical features and the results of any other 
investigations. 
 
Results - 126 EBUS-TBNA examinations were performed to investigate IML. A 
positive pathological diagnosis was made following EBUS-TBNA in 54 cases (42.9%). 
When the results of further investigations and variable radiological follow up was 
included, the final sensitivity of EBUS-TBNA to make a diagnosis in IML was 80.3% 
(95% CI 68.7% to 89.1%).  
 
Conclusions - This study confirms that EBUS-TBNA has a good yield for both benign 
and malignant pathologies resulting in IML.  
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Introduction 
Isolated mediastinal lymphadenopathy (IML) is an increasingly common finding 
associated with the ubiquity of thoracic CT imaging. For the purpose of this study, we  
defined IML as the presence of mediastinal or hilar lymph node enlargement (either in 
single or multiple lymph node stations), without the presence of an obvious associated 
malignancy or alternative causation at the time of investigation.  
 
IML comprises a heterogenous group of conditions with varying aetiology including 
occult metastatic malignancy, benign granulomatous disorders, lymphoproliferative 
disorders, or reactive lymphadenopathy that may relate to underlying conditions such 
as interstitial lung disease or rheumatological disorders [1].  Patients identified as 
having IML on imaging will have a provisional diagnosis formulated upon clinical and 
radiological features, however there is often a need to establish a tissue diagnosis 
before proceeding with management. These patients are commonly referred to 
Respiratory Services for further investigation. 
 
Surgical mediastinoscopy has previously been regarded as the ‘gold standard’ to 
obtain tissue to make a pathological diagnosis in mediastinal adenopathy. However, 
this technique does not allow access to all lymph node stations and is associated with 
a not-insignificant morbidity as it is performed under general anaesthesia [2]. The utility 
of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) 
as an alternative to conventional mediastinoscopy for the diagnosis and staging of 
patients with suspected lung cancer has been firmly established [3, 4]. EBUS-TBNA is 
a technique that utilises endoluminal ultrasound technology during bronchoscopy to 
identify lymph nodes that are amenable to sampling using trans-bronchial needle 
aspiration. Patient selection for this procedure is similar that for conventional 
bronchoscopy (FEV1 > 1.0L, Oxygen saturations >90% on room air and no 
coagulopathy or other contraindications to needle sampling) and the procedure can be 
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performed under sedation as opposed to general anaestheia. Recent studies have 
demonstrated superior sensitivity, cost savings and shorter time to treatment that may 
translate to a survival benefit when EBUS-TBNA is pursued as a first-line investigation 
for the investigation of non-small cell lung cancer (NSCLC) [5].  
 
There is also emerging evidence supporting the utility of EBUS-TBNA to investigate 
IML with reported sensitivities of EBUS-TBNA ranging from 82.7% to 92% [1, 6]. 
Individual studies have reported variable sensitivity of EBUS-TBNA according to the 
aetiology of IML, including 83 – 85% in sarcoidosis and 38% in lymphopriliferative 
disorders [7, 8, 9].  
 
A particular difficulty encountered with the use of EBUS-TBNA in the investigation of 
IML is the high prevalence of ‘non-diagnostic’ samples, where only benign or reactive 
cells are obtained following cytological examination. Reactive mediastinal 
lymphadenopathy is relatively common and samples obtained in these cases are 
difficult to differentiate from low-grade lymphoma. This presents a dilemma to clinicians 
and may necessitate further investigations in cases where samples from EBUS-TBNA 
are non-diagnostic.  
 
Strategies employed to overcome the problem of non-diagnostic samples following 
EBUS-TBNA in published studies to date range from mediastinoscopy in all patients 
(as a comparator or gold standard) to clinical and radiological surveillance [1, 6]. These 
patients however formed part of a ‘trial population’, and were able to undergo both 
EBUS-TBNA and/or mediastinoscopy as a comparator. However, this is not always 
the case in clinical practice due to patient fitness and preference. 
 
There is limited evidence on the performance EBUS-TBNA to investigate IML in routine 
clinical practice. We aim to assess the diagnostic yield of EBUS-TBNA for IML in a 
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consecutive patient series. We also report the requirement for subsequent 
investigations (including mediastinoscopy) and follow-up strategies in cases where 
EBUS-TBNA yielded non-diagnostic samples. 
 
Methods 
Sequential EBUS examinations performed over a 4-year period from January 2011 to 
December 2014 at the Royal Infirmary of Edinburgh (RIE) – a tertiary referral centre - 
were retrospectively reviewed. Referrals for EBUS examinations were accepted from 
a range of specialties. Procedures performed for the staging of lung cancer or for the 
investigation of a known/suspected primary malignancy (identified on prior cross-
sectional imaging) with associated mediastinal lymphadenopathy were excluded from 
analysis. Patients were identified as having IML if there was evidence of 
mediastinal/hilar lymphadenopathy on cross-sectional imaging with no evidence of 
malignant aetiology identifiable on other imaging modalities or investigations to date.  
 
All patients had a pre-sampling Computed Tomography (CT) scan of the thorax. 
Mediastinal lymph nodes were classified according to the International Staging 
System.  All cases that proceeded to EBUS-TBNA had a minimum lymph node 
diameter of >10mm. 
 
All procedures were performed or supervised by one of two lead lung cancer 
physicians. Intubation was performed via the oral route and sedation was achieved 
with intravenous Midazolam and Alfentanyl. EBUS was performed with the Olympus 
BFUS 260 endoscope and 22-gauge cytology needle. Images were achieved with an 
Olympus Prosound α10 ultrasound machine. Sonographic nodal characteristics and 
number of passes were not recorded. Nodal samples were transferred into ‘Cytolyt’ 
fixative and processed, as previously described utilising a ‘thin layer’ technique and 
subsequent cell blocks [10]. Further sections from cell blocks were stained 
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histochemically or immunohistochemically as indicated by the features identified. 
 
A final diagnosis was made using cytopathology from EBUS-TBNA correlated with 
clinical picture at presentation and follow-up. In cases where a pathological diagnosis 
was not obtained following EBUS-TBNA, the decision to organise further investigations 
was made by the referring teams. Referring teams made a final diagnosis based on 
any additional pathology, clinical features and multi-disciplinary team decision. 
Information on further investigations and radiological follow-up were obtained from 
review of medical records. Statistical analysis was performed using GraphPad Prism 
software. 
 
Results 
A total of 826 EBUS examinations were performed during the 4-year study period. 700 
examinations were excluded following identification of radiologically evident primary 
malignancy. The remaining 126 patients were classified as having IML and were 
included in the study. Median age was 60 and 87 patients (69.0%) were male. Patient 
characteristics are summarised in TABLE 1.  
 
Results from EBUS-TBNA aspirates are summarised in FIGURE 1. A Pathological 
diagnosis was achieved following EBUS-TBNA in 54 cases (42.9%). EBUS-TBNA 
aspirates yielded benign or reactive lymphoid cells, not confirming a pathological 
diagnosis - in 72 cases (57.1%) while nodal sampling was insufficient or not achieved 
in 10 cases (7.9%). 
 
Malignant Disease 
A total of 41 patients (32.5%) had a final diagnosis of malignancy in our data set 
(FIGURE 2). EBUS-TBNA yielded samples diagnostic of malignancy in 31 cases 
(24.6%). Features suggestive of malignant disease were identified following EBUS-
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TBNA in 8 cases (6.3%) and further investigations were performed to confirm the 
diagnosis in 5 (3.9%) of these patients (two further patients received a consensus 
clinical diagnosis and one patient initially identified as having an EBUS-TBNA sample 
suspicious for malignancy was diagnosed with a viral myocarditis) (TABLE 2). Three 
further cases of malignancy were diagnosed following further investigations in patients 
where EBUS-TBNA yielded aspirates containing benign or reactive cells only. 
 
A final diagnosis of lymphoma was made in 4 patients (3.2%). EBUS-TBNA provided 
a pathological diagnosis of lymphoma in 1 case (0.8%), suggested this diagnosis in 
two cases (1.6%, who went on to have confirmatory investigations) but missed a 
diagnosis of lymphoma in 1 (0.8%). 
 
Granulomatous Lymphadenitis 
Granulomatous lymphadenitis was identified in 23 cases (18.3%) following EBUS-
TBNA. Sarcoidosis was the final diagnosis in 19 of these cases (15.1%), with 1 patient 
proceeding to have a confirmatory mediastinoscopy after EBUS-TBNA. The remainder 
of diagnoses were mediastinal TB (negative TB culture, clinical diagnosis) and 
Idiopathic Interstitial Pneumonia (sarcoidosis was the initial differential diagnosis 
considered, however a consensus diagnosis of Idiopathic Interstitial Pneumonia was 
made upon review of imaging). One patient underwent radiological follow up and one 
patient was lost to follow up.f 
 
Samples where pathological diagnosis was not achieved 
EBUS-TBNA did not yield a pathological diagnosis 72 cases (57.1%). Further 
investigations to ascertain the diagnosis in these cases were performed in 16 cases 
(12.7%), of which 5 were mediastinoscopies (TABLE 2). Further investigations in 
cases with non-diagnostic samples yielded a pathological diagnosis in only 13 cases 
(10.3%) (FIGURE 3).   
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The remaining 59 cases (46.8%) were deemed to have reactive lymphadenopathy and 
underwent a combination of further investigations or radiological follow-up with CT 
chest or Positron Emission Tomography – Computed Tomography (PET-CT). Of these 
patients, 3 underwent repeat fibre-optic bronchoscopy and 1 underwent EUS but these 
procedures did not yield a pathological or alternative diagnosis.  
 
Performance 
Ideally, sensitivity of EBUS-TBNA would have been assessed against the accepted 
gold standard (mediastinoscopy) as a comparator. Given however that not all patients 
in this cohort underwent further investigations, we adopted a pragmatic approach 
towards a sensitivity calculation. 
 
A ‘True Positive’ was accepted as the ability of EBUS-TBNA to identify a pathological 
diagnosis when there was one apparent (ie. Malignant cells or granulomatous 
lympadenitis in sarcoidosis). ‘True Negatives’ were deemed to be cases of reactive 
lymphadenopathy where EBUS-TBNA idenitified cytologically benign or reactive 
lymphoid cells only. 
 
Including cases where nodal sampling was not achieved, the sensitivity of EBUS-
TBNA for a diagnosis in our cohort was 80.3% (95% CI 68.7% to 89.1%).  
 
Discussion 
A considerable number of EBUS-TBNA examinations (15.3%, 126/826) were 
performed for the investigation of IML.  
 
A significant proportion of patients in our cohort had a final diagnosis of malignant 
disease (41 cases, 32.5%) indicating that occult malignancy is an important cause of 
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mediastinal lymphadenopathy.  Malignant disease was identified in 8 cases (6.3%) 
where EBUS-TBNA failed to achieve a pathological diagnosis (including 3 cases of 
lymphoma), highlighting the importance of further investigations to obtain a 
pathological diagnosis where malignancy is suspected even when FNA cytology is 
negative.  
 
In our unselected series, the overall sensitivity of EBUS-TBNA to yield a pathological 
diagnosis was 80.3%, in comparison to the sensitivity reported by other studies: 92% 
by Navani et al, and 82.7% by Evison et al [1, 6]. The large number of negative 
examinations in our cohort could be attributed to the high proportion of patients with 
reactive lymphadenopathy (46.8%, 59/126 cases) - similar to the proportion reported 
by Evison et al (48% reactive lymphadenopathy). The mean age of our study 
population was 60 compared to 58.6 in Evison et al, providing further evidence of an 
association between increasing age and reactive lymphadenopathy [1].  
 
Seventeen (13.5%) patients in total cohort underwent further investigations, 5 of which 
were mediastinoscopies (one of these was confirmatory despite a positive EBUS-
TBNA sample for granulomatous lymphadenitis). It can be postulated that diagnostic 
EBUS-TBNA helped avoid mediastinoscopy in a proportion of patients in this cohort. 
In our cohort, patients with non-diagnostic samples who did not undergo further 
investigations underwent radiological follow-up or were followed up by the referring 
clinical teams. There was variability in modality used (CT Chest or PET-CT) and 
duration of follow-up. 
 
The retrospective nature of our study limits our ability to correct for selection bias but 
patient age was a likely determinant in a low threshold for referral for EBUS-TBNA 
compared to threshold for referral for subsequent mediastinoscopy when pathology 
from EBUS-TBNA was non-diagnostic (only 5 in our cohort). The retrospective nature 
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of our study also limited our ability to access information on rationale behind follow-up 
strategies pursued by referring teams. Generally there was wide variability between 
the decision to pursue further investigations or pursue a surveillance strategy using 
cross-sectional imaging. We believe this is reflective of current clinical practice 
however we would have preferred to have been able to report the rationale behind 
these decisions. The lack of a comparator such as mediastinoscopy in ptients with 
non-diagnostic samples limits our interpretation of performance of EBUS-TBNA, 
allowing us to report an estimated sensitivity but not a specificity, negative or positive 
predictive values. Lastly, given variability in the decision to purse further investigations 
or surveillance, it is possible that some pathological diagnoses may have been missed 
and reactive lymphadenopathy may have been overcalled. 
 
This study confirms that EBUS-TBNA has a good yield for both benign and malignant 
pathologies resulting in IML and should be considered as a non-invasive alternative to 
mediastinoscopy, particularly in cases where lymphoma is thought less likely. 
Requirement for further investigation and/or surveillance following non-diagnostic 
cytology from EBUS-TBNA should be reviewed on a case-by-base basis in 
collaboration with referring teams in a multi-disciplinary forum. When practical, a tissue 
diagnosis should be pursued, particularly if there are concerns that the diagnosis could 
be malignancy. A more clearly defined surveillance strategy to standardise follow-up 
cases where a tissue diagnosis is not obtained is advisable. This could mirror the 
strategy used to follow-up pulmonary nodules identified on cross-sectional imaging of 
the chest. Future work focusing on performance of surveillance strategies following 
non-diagnostic EBUS-TBNA would aid the development of a comprehensive and safe 
strategy for the investigation and management of IML. 
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TABLE 1 – Patient Demographics (n=126); Hx – History. 
Smoking status 
     Non smokers                                                  52 (41.2%) 
     <10 pack year Hx                                           19 (15.1%) 
      >10 pack year Hx                                          40 (31.7%) 
      Not available                                                 15 (11.9%) 
 Ethnicity 
    White British                                                    108 (79.4%) 
    White European                                               7 (5.6%) 
    Black African                                                    2 (1.6%) 
    Indian                                                               4 (3.2%) 
    Pakistani                                                          4 (3.2%)     
    Other                                                                1 (0.8%) 
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FIGURE 1 - Aspirates obtained following EBUS-TBNA
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Lymphadenitis
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FIGURE 2 - Malignant Diagnoses identified with EBUS-TBNA 
aspirates
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FIGURE 3 - Diagnoses Following Further Investigations in Cases 
with Non-Diagnostic EBUS-TBNA
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TABLE 2 – Summary of Further Investigations and Final Diagnosis according to initial 
cytology following EBUS-TBNA 
Initial 
Cytology 
Diagnostic 
Category; Number 
that underwent 
further 
investigatiosn 
Further 
Investigation 
Pathological 
Diagnosis 
Non-
Diagnostic 
Suspicious for 
Malignancy (8);  
5 underwent further 
investigations 
Surgical resection (1) Sarcoma 
Core Biopsy of 
Peripheral Lymph 
Node (1) 
Lymphoma 
Bone Marrow Biopsy 
(1) 
Lymphoma 
Fibre-optic 
Bronchiscopy at 3 
months (1) 
Squamous cell 
carcinoma 
EBUS-TBNA at 6 
months (1) 
Adenocarcinoma 
10 underwent 
further 
investigations 
Lymph node biopsy 
(1) 
Lymphoma 
Mediastioscopy – 
non-diagnostic (1) 
followed by VATS 
Biopsy 
Reactive 
Lymphadenopathy 
- Inflammation and 
Fibrosis with 
Aspergillus 
colonisation 
Mediastinoscopy (1) Reactive 
Lymphadenopathy 
- Sinus 
Histiocytosis 
Mediastinoscopy (2); 
1 mediastinoscopy 
was non-diagnostic 
Sarcoidosis 
VATS Biopsy (1) Lepidic 
Adenocarcinoma 
EBUS (1) Adenocarcinoma 
EUS (1) Reactive 
EUS-B (1 – non-
diagnostic) 
Sarcoidosis 
(Clinical diagnosis) 
Skin Biopsy (1) Sarcoidosis 
Insufficient/No 
Nodal 
Sampling 
2 underwent further 
investigations 
Mediastinoscopy (1) Sarcoidosis 
Skin biopsy (1) Sarcoidosis 
VATS – Video-asisted thorascopic surgery; EUS – Endoscopic Ultrasound Fine-Needle 
Aspiration; EUS-B – Endoscopic Ultrasound Fine-Needle Aspiration with an 
Endobronchoscope 
